Across 88 CTIS ovarian, fallopian tube, and primary peritoneal cancer Phase II–III trial records from 2024–2026, site activity is concentrated in a relatively small set of academic gynecologic oncology and early-phase oncology centers. UZ Leuven was the clearest repeat site participant, while country-level allocation was led by Italy, Germany, France, Spain, and Belgium, which together contributed 10,073 summed participant allocations in the quantified top-five country analysis.
The top site ranking is based on repeated site participation across ovarian/fallopian/primary peritoneal cancer Phase II–III geography records. UZ Leuven was the strongest repeat site with 8 detected participations, representing 9.1% of the 88 included trial records. The rest of the top group clustered tightly between 3 and 4 detected participations each.
The site landscape is not dominated by one mega-center. Instead, ovarian trial access appears distributed across repeat specialist centers, with Belgium showing especially strong repeat institutional presence through UZ Leuven, Institut Jules Bordet, Saint-Luc, and Gent-linked sites.
Of the 88 included records, 56 were Phase II and 32 were Phase III. Phase II therefore represented 63.6% of the dataset, while Phase III represented 36.4%. By year, 2024 accounted for 56 records, or 63.6% of all included records.
The ovarian cancer development footprint in CTIS is more exploratory than confirmatory: nearly two-thirds of records are Phase II. For site strategy, this means early-phase and translational oncology capability is likely as important as large randomized Phase III capacity.
The top five countries accounted for 10,073 summed participant allocations across repeated country records. Italy had the highest participant allocation total with 2,765, followed by Germany with 2,359, France with 2,301, Spain with 1,865, and Belgium with 783. Country coverage was broadest in Spain by repeated country records, while France led summed site-slot coverage.
| Country | Participants | Site slots | Country records | Share of top-five participants |
|---|---|---|---|---|
| Italy | 2,765 | 385 | 41 | 27.5% |
| Germany | 2,359 | 284 | 32 | 23.4% |
| France | 2,301 | 463 | 39 | 22.8% |
| Spain | 1,865 | 359 | 48 | 18.5% |
| Belgium | 783 | 131 | 35 | 7.8% |
The quantified picture changes the interpretation: Italy leads on participant allocation, France leads on site-slot coverage, and Spain leads on repeated country coverage. Germany remains one of the largest allocation markets, but the overall EU footprint is multi-country rather than Germany-only.
The geography records include ovarian cancer, fallopian tube cancer, primary peritoneal cancer, high-grade serous ovarian cancer, endometrioid ovarian cancer, recurrent ovarian cancer, and broader solid-tumor protocols that included ovarian cancer. This creates a mixed site landscape: some sites appear through gynecologic-oncology-specific studies, while others appear through broader early-phase oncology programs.
The top-site list should be interpreted as a combined gynecologic-oncology and early-phase oncology network. Some high-activity sites are ovarian specialty centers, while others are broad drug-development units that capture ovarian patients within basket or multi-tumor protocols.
European ovarian cancer Phase II–III trial participation is distributed across a specialist network rather than centralized in a single country or site. The quantified top-five country footprint shows 10,073 summed participant allocations, led by Italy, Germany, France, Spain, and Belgium, while the top site pattern still points to repeat specialist gynecologic-oncology and early-phase oncology centers.
For ovarian cancer development planning, the most useful EU site strategy is not simply to select the largest oncology markets. The data points toward a hybrid model: large-country reach for patient allocation, combined with repeat gynecologic-oncology reference sites and early-phase oncology units for complex, biomarker-driven, or basket-style protocols.